Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 5.00 (8.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed Placing and Fund Raising to raise c.£20m

1 Oct 2015 07:00

RNS Number : 8342A
NetScientific PLC
01 October 2015
 

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. 

 

PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) IS NOT AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY ORDINARY SHARES OR OTHER SECURITIES OF THE COMPANY AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER. ORDINARY SHARES OR OTHER SECURITIES OF THE COMPANY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OF AMERICA ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION AND THE ORDINARY SHARES DESCRIBED HEREIN WILL BE SOLD IN ACCORDANCE WITH ALL APPLICABLE LAWS AND REGULATIONS.

 

 

1 October 2015

 

NetScientific plc

(the "Company")

 

Proposed Placing to raise approximately £18.0 million

Additional Fundraising to raise up to approximately £2.0 million

Proposed waiver of Rule 9 of The City Code on Takeovers and Mergers (the "Code")

Notice of General Meeting

 

NetScientific plc (AIM:NSCI), a transatlantic biomedical healthcare group with a differentiated investment strategy focused solely on digital health, diagnostics and therapeutics, announces a conditional Placing to raise approximately £18.0 million before expenses and an Additional Fundraising to raise up to approximately £2.0 million, primarily to accelerate the development of its two lead portfolio companies, Vortex Biosciences and Wanda, towards significant value inflection milestones and exits. Neither the Placing nor the Additional Fundraising are underwritten.

 

A Circular setting out further details on the Placing, Additional Fundraising and the Rule 9 Waiver is expected to be posted to shareholders no later than 23 October 2015, with Admission expected to occur no later than 30 November 2015.

 

The Company has today separately released its half year results for the six months ended 30 June 2015

 

Details of the Fundraising

 

· Placing - Placing of 15,000,000 New Ordinary Shares at 120p each to raise approximately £18.0m before expenses by means of a placing by Investec Bank and Liberum

· Additional Fundraising - Up to 1,666,667 New Ordinary Shares at 120p to raise up to approximately £2.0 million. The Additional Fundraising will be by way of a private placing or subscription at the Directors' discretion, and is not open to the public

· Issue Price - The Issue Price of the New Ordinary Shares at 120 pence per Ordinary Share, represents a discount of 19.5 per cent. to the closing middle market share price of 149 pence on 30 September 2015

· Notice of General Meeting - Due to the size of the Placing, Shareholder approval is required which will be sought at the General Meeting

· Rule 9 Waiver - Given the level of investment by Woodford Investment Management LLP ("Woodford") in the proposed Placing, assuming the Placing receives all necessary approvals, it will result in Woodford owning more than 30 per cent. of the total voting rights of the Company. This investment requires a waiver by the Takeover Panel under Rule 9 of the Code and must be approved by Independent Shareholders under Rule 9 of the Code and such approval will be sought at the General Meeting

· The Directors unanimously recommend Shareholders to vote in favour of the Resolutions

 

 

Francois R. Martelet, M.D., Chief Executive Officer of NetScientific, said:

 

"Our core portfolio companies, led by Vortex and Wanda, have made significant progress over the past 12 months, as described in today's results. The proposed funding would make a real difference to the rate at which we can accelerate Vortex and Wanda and we recommend Shareholders to vote positively at the General Meeting".

-Ends-

 

 

For more information, please contact:

 

NetScientific plc

 

François R. Martelet, M.D., CEO

Tel: +44 (0)20 3514 1800

Peter Thoms, CFO

 

 

 

Investec Bank plc (NOMAD, broker and joint bookrunner)

Tel: +44 (0)20 7597 4000

Gary Clarence / Daniel Adams

 

 

 

Liberum Capital Limited (joint bookrunner)

Tel: +44 (0)20 3100 2000

David Parsons / Christopher Britton

 

 

 

Instinctif Partners

Melanie Toyne-Sewell

Rosanna Forrest

Tel: +44 (0)20 7457 2020 or netscientific@instinctif.com

   

 

 

Investec Bank plc, which is authorised in the United Kingdom by the Prudential Regulatory Authority and regulated by the FCA and the Prudential Regulatory Authority, is acting exclusively for the Company and no other person in connection with the Placing. Investec Bank plc is not acting for the Company or anyone else in connection with the Additional Fundraising. Investec Bank plc's responsibilities as the Company's nominated adviser under the AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange and are not owed to the Company or to any Director or to any person in respect of his decision to acquire Placing Shares or Additional Fundraising Shares in reliance on any part of this document. No representation or warranty, express or implied, is made by Investec Bank plc about any of the contents of this document and, without limiting the statutory rights of any person to whom this document is issued, no liability whatsoever is accepted by Investec Bank plc for the accuracy of any information or opinions contained in this document or for the omission of any material information. Investec Bank plc will not be offering advice nor will it be responsible for providing client protections to recipients of this document in respect of the Placing and Additional Fundraising.

Liberum Capital Limited, which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company and no other person in connection with the Placing. Liberum Capital Limited is not acting for the Company or anyone else in connection with the Additional Fundraising. No representation or warranty, express or implied, is made by Liberum Capital Limited about any of the contents of this document and, without limiting the statutory rights of any person to whom this document is issued, no liability whatsoever is accepted by Liberum Capital Limited for the accuracy of any information or opinions contained in this document or for the omission of any material information. Liberum Capital Limited will not be offering advice nor will it be responsible for providing client protections to recipients of this document in respect of the Placing and Additional Fundraising.

 

Proposed Placing to raise approximately £18.0 million

Additional Fundraising to raise up to approximately £2.0 million

Proposed waiver of Rule 9 of The City Code on Takeovers and Mergers (the "Code")

Notice of General Meeting

 

1. Introduction

The Company has today announced that it is proposing to raise approximately £18.0 million (before expenses) by way of the Placing by Investec Bank and Liberum of New Ordinary Shares with existing and new institutional investors and to raise up to a further £2.0 million through the Additional Fundraising. The net funds from the Placing will primarily be used to accelerate the development of its two lead portfolio companies, Vortex Biosciences and Wanda, towards significant value inflection milestones and exits. In addition, NetScientific intends to manage, in a controlled manner, its other majority-owned assets and minority investments.

The Placing and Additional Fundraising is conditional, amongst other things, on the passing of the Resolutions (other than the Whitewash Resolution) by Shareholders and the passing of the Whitewash Resolution by Independent Shareholders at the General Meeting, notice of which will be set out in a circular to be posted to Shareholders ("Circular") as soon as possible after this Announcement. Neither the Placing nor the Additional Fundraising are underwritten.

Rule 9 Waiver

Woodford is currently a beneficial holder of approximately 29.4 per cent. of the Company's current issued share capital. Woodford has agreed to subscribe for 12,500,000 New Ordinary Shares, being an amount that would increase its percentage holding of the Company immediately following the Placing to over 30 per cent. which, without a waiver of the obligations under Rule 9 of the Code ("Rule 9 Waiver"), would oblige Woodford (and any persons acting in concert with it) to make a general offer to Shareholders of the Company under Rule 9 of the Code (a "Rule 9 Offer").

Following Admission, it is expected that Woodford will have a shareholding of approximately 45.3 per cent of the Company's enlarged share capital, excluding any New Ordinary Shares that may be issued through the Additional Fundraising.

The Company will apply for a waiver of the requirement for Woodford to make a Rule 9 Offer under Note 1 to the Notes on Dispensations from Rule 9 of the Code, which states that when the issue of new securities in consideration for an acquisition or a cash subscription would otherwise result in an obligation to make a Rule 9 Offer, the Takeover Panel will normally grant a waiver if, inter alia, the shareholders of a company who are independent of the person who would otherwise be required to make an offer and any person acting in concert with him or her pass an ordinary resolution on a poll at a general meeting approving the proposals giving rise to the obligation to make a Rule 9 Offer and the Takeover Panel has agreed to such a waiver being sought.

There can be no guarantee that the Independent Shareholders will pass the Whitewash Resolution or that the Takeover Panel will grant the waiver of the requirement for Woodford to make a Rule 9 Offer in connection with the Placing. If the Rule 9 Waiver is not granted or the Whitewash Resolution is not passed, the Placing will not be able to proceed in its current form and the Company will seek to pursue a different funding structure. In order to provide the necessary funding to its portfolio companies, it is likely that the Company will accelerate fundraising in its key subsidiaries through third party investment. In addition, licensing and/or sale of the minority investment technologies will be considered in order to maximise value to shareholders.

The Directors who hold Existing Ordinary Shares intend to vote in favour of the Resolutions in respect of the Existing Ordinary Shares held by them and which represent, in aggregate, approximately 0.3 per cent. of the Company's current issued share capital.

The Circular convening the General Meeting will contain additional information on the Code matters relevant to the Placing.

2. Current trading

Today the Company announced its results for the six months ended 30 June 2015. For that six month period the Company is reporting unaudited revenues of £0.5 million and an after tax loss of £5.3 million. Cash on the balance sheet as at 30 June 2015 was £11.1 million. Progress in all of the Company's investments continues in line with the Board's expectations.

3. Summary of Vortex and Wanda

Vortex Biosciences

Vortex Biosciences is a US based cancer diagnostic company, developing a novel liquid biopsy diagnostic instrument for circulating tumour cell enrichment, collection and analysis. The technology enables researchers and clinicians to non-invasively to capture, analyse, identify, and enumerate tumour cells for use in downstream clinical applications such as genetic analysis, monitoring disease progression and drug treatment effectiveness.

 

One of the key milestones for Vortex will be the launch of the VTX-1 into clinical research labs, expected during 2016.

In 2015, Vortex hired additional engineers and scientists to complete the development of its VTX-1 instrument, which is scheduled for shipment to Beta sites by the end of 2015. Collaborations with key opinion leaders including UCLA, Stanford and Harvard, in the field has resulted in demand for the new Beta VTX-1. In addition, Vortex filed new patent applications and received grant in four of its ten patent families.

Wanda

Wanda is a US based company which provides a cloud-based clinical decision support software solution to help healthcare providers improve the quality of outpatient care and reduce the costs associated with managing chronic diseases.

 

Its software aims to reduce the economic burden of hospital readmissions by providing tools to monitor and manage patients with chronic diseases, initially patients with congestive heart failure. The platform technology builds upon a patented predictive analytics and knowledge engine that utilises information from in-home and remote monitoring devices used by patients.

 

Following successful pilots with Triventis Health since May, first revenues from pilot programmes are expected in Q4 2015.

 

As part of a focused effort on strengthening portfolio company management, Steve Curd was appointed CEO of Wanda on 14 September. He has more than 20 years' experience in driving growth in digital healthcare companies, commercialising products and delivering exits.

 

The key milestones for Wanda is patient uptake and Wanda is looking to accelerate this during 2016 and 2017.

 

4. Reasons for the Placing and Additional Fundraising and use of proceeds

The Directors believe that there is significant embedded value within its portfolio companies, in particular Vortex and Wanda, which require additional capital investment in order to reach value inflection milestones. The Group will focus on further funding Vortex and Wanda toward commercialisation and potential exit opportunities. In addition, NetScientific intends to manage, in a controlled manner, its other majority-owned assets and minority investments.

The Directors believe that the flexibility provided by a non-pre-emptive placing makes it the most appropriate fundraising structure for the Company at this time.

5. Principal Terms of the Placing

The Company has conditionally raised £18.0 million before expenses by the conditional Placing of 15,000,000 Placing Shares at the Issue Price to the Placees. The Placing is not underwritten.

The Placing is conditional, among other matters, upon:

(i) the passing of all of the Resolutions (other than the Whitewash Resolution) by Shareholders;

(ii) the Takeover Panel providing a Rule 9 Waiver, subject to the Whitewash Resolution being approved by Independent Shareholders;

(iii) the passing of the Whitewash Resolution by Independent Shareholders;

(iv) the Placing Agreement becoming or being declared unconditional in all respects and not having been terminated in accordance with its terms before Admission; and

(v) Admission becoming effective by no later than 8.00 a.m. on 13 November 2015 (or such later date as the Company, Investec Bank and Liberum may agree, provided that such date shall not extend beyond 8.00 a.m. on 30 November 2015). Admission may occur at an earlier date, which if achievable, will be set out in the Circular.

If any of the conditions are not satisfied (or waived), the Placing Shares will not be issued and all monies received from the Placees will be returned to them (at the Placees' risk and without interest) as soon as possible thereafter.

The Placing Shares are not being allotted subject to clawback. The Placing Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of their issue.

6. Principal Terms of the Additional Fundraising

In addition to the Placing, the Company is targeting a maximum further raise of £2.0 million (before expenses) by way of an Additional Fundraising of up to 1,666,667 New Ordinary Shares at the Issue Price. The Additional Fundraising will be by way of a private placing or subscription at the Directors' discretion, and is not open to the public. The Additional Fundraising will be available only to existing institutional or other investors which the Directors are satisfied can lawfully invest on a private placement basis.

The Additional Fundraising is not underwritten and neither Investec Bank nor Liberum is acting for the Company, or any other person, in connection with the Additional Fundraising.

The Additional Fundraising Shares will be allotted and issued fully paid and will, on issue, rank pari passu with the Existing Ordinary Shares in issue, including the right to receive, in full, all dividends and other distributions thereafter declared, made or paid after the date of issue together with all rights attaching to them and free from all liens, charges and encumbrances of any kind.

Related Party Transaction

The participation of Woodford in the Placing constitutes a related party transaction under the AIM Rules for Companies by virtue of Woodford being a substantial shareholder in the Company. The Directors consider, having consulted with Investec Bank, its nominated adviser, that the terms of the transaction are fair and reasonable in so far as its Shareholders are concerned.

Recommendation

The Directors believe that the Placing, Rule 9 Waiver and Additional Fundraising and the passing of the Resolutions are in the best interests of the Company and Shareholders, taken as a whole. Accordingly the Directors unanimously intend to recommend Shareholders (or Independent Shareholders as the case may be) vote in favour of the Resolutions, as they intend to do in respect of their aggregate beneficial holdings of 90,526 Ordinary Shares, representing 0.3 per cent of the Existing Ordinary Shares.

The Placing and Additional Fundraising are conditional, among other things, upon the passing of the Resolutions at the General Meeting. Shareholders should be aware that if the Resolutions are not approved at the General Meeting by the Shareholders or the Independent Shareholders (as applicable), the Placing and Additional Fundraising will not proceed.

Definitions

The following definitions apply throughout this document, unless the context requires otherwise:

"Act"

"Additional Fundraising"

 

Companies Act 2006 (as amended)

the issue, separate to the Placing, of up to a further 1,666,667 New Ordinary Shares to existing institutional or other investors to whom such shares can lawfully be offered on a private placement basis

"Additional Fundraising Shares"

the New Ordinary Shares to be issued pursuant to the Additional Fundraising

"Admission"

the admission of the New Ordinary Shares to trading on AIM in accordance with the AIM Rules for Companies

"AIM Rules for Companies"

the AIM Rules for Companies and guidance notes as published by the London Stock Exchange from time to time

"AIM"

the AIM market operated by London Stock Exchange

"Board" or "Directors"

the directors of the Company as at the date of this document

"Business Day"

a day other than a Saturday, Sunday or public holiday in England when banks in London are open for business

"Circular"

as defined in this Announcement

"Code"

The City Code on Takeovers and Mergers

"Company" or "NetScientific"

NetScientific plc

"CREST member"

a person who has been admitted to CREST as a system-member (as defined in the CREST Manual)

"CREST Regulations"

the Uncertificated Securities Regulations 2001 (SI 2001/3755) (as amended)

"CREST"

the relevant system (as defined in the CREST Regulations) in respect of which Euroclear is the operator (as defined in the CREST Regulations)

"Enlarged Share Capital"

the entire issued share capital of the Company following the issue of New Ordinary Shares pursuant to the Fundraising, assuming the maximum number of Additional Fundraising Shares are issued

"Euroclear"

Euroclear UK & Ireland Limited

"Existing Ordinary Shares"

the 35,902,020 Ordinary Shares in issue on the date of this document

"FCA"

the Financial Conduct Authority of the UK

"FSMA"

Financial Services and Markets Act 2000 (as amended)

"Fundraising"

the Placing and the Additional Fundraising

"General Meeting"

the General Meeting of the Company, notice of which will be set out in the Circular

"Group"

the Company and its subsidiaries

"Independent Shareholders"

all Shareholders other than Woodford (and anyone acting in concert with it)

"Investec Bank"

Investec Bank plc

"Liberum"

Liberum Capital Limited

"London Stock Exchange"

London Stock Exchange plc

"New Ordinary Shares"

the new Ordinary Shares being issued in relation to the Fundraising

"Notice of General Meeting"

the notice convening the General Meeting to be set out in the Circular

"Issue Price"

120 pence per New Ordinary Share

"Ordinary Shares"

ordinary shares of 5p each in the capital of the Company

"Placees"

subscribers for Placing Shares

"Placing"

the placing of 15,000,000 New Ordinary Shares at 120 pence per share, the details of which are set out in the Circular

 "Placing Agreement"

the agreement entered into between the Company, Investec Bank and Liberum in respect of the Placing dated 1 October 2015

"Placing Shares"

the 15,000,000 New Ordinary Shares to be issued pursuant to the Placing

"Resolutions"

the resolutions to be proposed at the General Meeting as set out in the Notice of General Meeting

"Rule 9 Offer"

as defined in this Announcement

"Rule 9 Waiver"

as defined in this Announcement

"Securities Act"

US Securities Act of 1933 (as amended)

"Shareholders"

the holders of Existing Ordinary Shares

"Takeover Panel"

the Panel on Takeovers and Mergers

"United Kingdom" or "UK"

the United Kingdom of Great Britain and Northern Ireland

"United States", "United States of America" or "US"

the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia and all areas subject to its jurisdiction

"Vortex" or "Vortex Biosciences"

Vortex Biosciences, Inc.

"Wanda"

Wanda, Inc.

"Whitewash Resolution"

the resolution to be proposed to Independent Shareholders as set out in the Notice of General Meeting to approve the Rule 9 Waiver

"Woodford"

as defined in this Announcement

 

APPENDIX - TERMS AND CONDITIONS OF THE PLACING

IMPORTANT INFORMATION FOR INVITED PLACEES ONLY REGARDING THE PLACING.

THIS ANNOUNCEMENT, INCLUDING THIS APPENDIX AND THE INFORMATION CONTAINED HEREIN (TOGETHER THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, THE REPUBLIC OF IRELAND, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT HAS NOT BEEN APPROVED BY THE LONDON STOCK EXCHANGE, NOR IS IT INTENDED THAT IT WILL BE SO APPROVED.

MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS DIRECTED ONLY AT: (A) PERSONS IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA") WHO ARE QUALIFIED INVESTORS AS DEFINED IN SECTION 86(7) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000, AS AMENDED ("QUALIFIED INVESTORS"), BEING PERSONS FALLING WITHIN THE MEANING OF ARTICLE 2(1)(e) OF DIRECTIVE 2003/71/EC AS AMENDED, INCLUDING BY THE 2010 PROSPECTUS DIRECTIVE AMENDING DIRECTIVE (DIRECTIVE 2010/73/EC) AND TO THE EXTENT IMPLEMENTED IN THE RELEVANT MEMBER STATE (THE "PROSPECTUS DIRECTIVE"); AND (B) IN THE UNITED KINGDOM, QUALIFIED INVESTORS WHO ARE PERSONS WHO (I) HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) (INVESTMENT PROFESSIONALS) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER"); (II) ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE ORDER; OR (III) ARE PERSONS TO WHOM IT MAY OTHERWISE BE LAWFULLY COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS").

THIS ANNOUNCEMENT AND THE INFORMATION IN IT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. PERSONS DISTRIBUTING THIS ANNOUNCEMENT MUST SATISFY THEMSELVES THAT IT IS LAWFUL TO DO SO. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. THIS ANNOUNCEMENT DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN NETSCIENTIFIC PLC.

THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE INTO THE UNITED STATES. THE PLACING SHARES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT 1933, AS AMENDED (THE "SECURITIES ACT") OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. SUBJECT TO CERTAIN EXCEPTIONS AND AT THE SOLE DISCRETION OF THE COMPANY, THE PLACING SHARES ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN "OFFSHORE TRANSACTIONS" WITHIN THE MEANING OF, AND IN ACCORDANCE WITH, REGULATION S UNDER THE SECURITIES ACT AND OTHERWISE IN ACCORDANCE WITH APPLICABLE LAWS. NO PUBLIC OFFERING OF THE PLACING SHARES IS BEING MADE IN THE UNITED STATES, THE UNITED KINGDOM OR ELSEWHERE. NO MONEY, SECURITIES OR OTHER CONSIDERATION FROM ANY PERSON INSIDE THE UNITED STATES IS BEING SOLICITED AND, IF SENT IN RESPONSE TO THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT, WILL NOT BE ACCEPTED.

EACH PLACEE SHOULD CONSULT WITH ITS ADVISERS AS TO LEGAL, TAX, BUSINESS AND RELATED ASPECTS OF AN INVESTMENT IN PLACING SHARES. THE DISTRIBUTION OF THIS ANNOUNCEMENT, ANY PART OF IT OR ANY INFORMATION CONTAINED IN IT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS, AND ANY PERSON INTO WHOSE POSSESSION THIS ANNOUNCEMENT, ANY PART OF IT OR ANY INFORMATION CONTAINED IN IT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, SUCH RESTRICTIONS. 

No action has been taken by the Company, Investec Bank, Liberum or any of their respective affiliates, agents, directors, officers or employees that would permit an offer of the Placing Shares or possession or distribution of this Announcement or any other offering or publicity material relating to such Placing Shares in any jurisdiction where action for that purpose is required.

This Announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the United States (including its territories and possessions, any state of the United States and the District of Columbia), Canada, the Republic of Ireland, Australia, the Republic of South Africa, Japan or any other jurisdiction in which the same would be unlawful. No public offering of the Placing Shares is being made in any such jurisdiction.

All offers of the Placing Shares will be made pursuant to an exemption under the Prospectus Directive from the requirement to produce a prospectus. In the United Kingdom, this Announcement is being directed solely at persons in circumstances in which section 21(1) of the Financial Services and Markets Act 2000 (as amended) (the "FSMA") does not apply.

The Placing Shares have not been approved or disapproved by the US Securities and Exchange Commission, any state securities commission or other regulatory authority in the United States, nor have any of the foregoing authorities passed upon or endorsed the merits of the Placing or the accuracy or adequacy of this Announcement. Any representation to the contrary is a criminal offence in the United States. The relevant clearances have not been, nor will they be, obtained from the securities commission of any province or territory of Canada, no prospectus has been lodged with, or registered by, the Australian Securities and Investments Commission or the Japanese Ministry of Finance; the relevant clearances have not been, and will not be, obtained for the South Africa Reserve Bank or any other applicable body in the Republic of South Africa in relation to the Placing Shares and the Placing Shares have not been, nor will they be, registered under or offering in compliance with the securities laws of any state, province or territory of Australia, Canada, Japan or the Republic of South Africa. Accordingly, the Placing Shares may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction outside the United Kingdom.

Persons (including, without limitation, nominees and trustees) who have a contractual right or other legal obligations to forward a copy of this Announcement should seek appropriate advice before taking any action.

This Announcement should be read in its entirety. In particular, you should read and understand the information provided in this "Important Information" section of this Announcement.

By participating in the Placing, each person who is invited to and who chooses to participate in the Placing (a "Placee") will be deemed to have read and understood this Announcement in its entirety, to be participating, making an offer and acquiring Placing Shares on the terms and conditions contained herein and to be providing the representations, warranties, indemnities, acknowledgements and undertakings contained in this Appendix.

In particular, each such Placee represents, warrants, undertakes, agrees and acknowledges (amongst other things) that:

(1) it is a Relevant Person and undertakes that it will acquire, hold, manage or dispose of any Placing Shares that are allocated to it for the purposes of its business;

(2) in the case of a Relevant Person in a member state of the EEA which has implemented the Prospectus Directive (each, a "Relevant Member State") who acquires any Placing Shares pursuant to the Placing:

a) it is a Qualified Investor within the meaning of Article 2(1)(e) of the Prospectus Directive; andb) in the case of any Placing Shares acquired by it as a financial intermediary, as that term is used in Article 3(2) of the Prospectus Directive:(i) the Placing Shares acquired by it in the Placing have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than Qualified Investors or in circumstances in which the prior consent of Investec Bank or Liberum has been given to the offer or resale; or(ii) where Placing Shares have been acquired by it on behalf of persons in any member state of the EEA other than Qualified Investors, the offer of those Placing Shares to it is not treated under the Prospectus Directive as having been made to such persons; and(3) it is acquiring the Placing Shares for its own account or is acquiring the Placing Shares for an account with respect to which it exercises sole investment discretion and has the authority to make and does make the representations, warranties, indemnities, acknowledgements, undertakings and agreements contained in this Announcement; and(4) it understands (or if acting for the account of another person, such person has confirmed that such person understands) the resale and transfer restrictions set out in this Appendix; and(5) except as otherwise permitted by the Company and subject to any available exemptions from applicable securities laws, it (and any account referred to in paragraph 3 above) is outside the United States acquiring the Placing Shares in offshore transactions as defined in and in accordance with Regulation S under the Securities Act.

 

No prospectus

No prospectus or other offering document has been or will be submitted to be approved by the FCA in relation to the Placing or the Placing Shares and Placees' commitments will be made solely on the basis of the information contained in this Announcement and any information publicly announced through a Regulatory Information Service (as defined in the AIM Rules for Companies (the "AIM Rules")) by or on behalf of the Company on or prior to the date of this Announcement (the "Publicly Available Information") and subject to any further terms set forth in the contract note to be sent to individual Placees.

Each Placee, by participating in the Placing, agrees that the content of this Announcement is exclusively the responsibility of the Company and confirms that it has neither received nor relied on any information (other than the Publicly Available Information), representation, warranty or statement made by or on behalf of Investec Bank, Liberum, the Company or any other person and none of Investec Bank, Liberum, the Company or any other person acting on such person's behalf nor any of their respective affiliates has or shall have any liability for any Placee's decision to participate in the Placing based on any other information, representation, warranty or statement. Each Placee acknowledges and agrees that it has relied on its own investigation of the business, financial or other position of the Company in accepting a participation in the Placing. Nothing in this paragraph shall exclude the liability of any person for fraudulent misrepresentation.

 

Details of the Placing Agreement and the Placing Shares

Investec Bank and Liberum (together the "Banks" and each a "Bank") have today entered into a placing agreement (the "Placing Agreement") with the Company under which, on the terms and subject to the conditions set out in the Placing Agreement, each of the Banks, as agent for and on behalf of the Company, has agreed to use their reasonable endeavours to procure Placees for the Placing Shares at the Placing Price.

The Placing Shares will, when issued, be subject to the articles of association of the Company and credited as fully paid and will rank pari passu in all respects with the existing issued ordinary shares of five pence per share ("Ordinary Shares") in the capital of the Company, including the right to receive all dividends and other distributions declared, made or paid in respect of such Ordinary Shares after the date of issue of the Placing Shares.

As part of the Placing, the Company has agreed that it will not for a period of 90 days after Admission (save pursuant to the Additional Fundraising as defined in this Announcement), offer, issue, sell, contract to sell, issue options in respect of or otherwise dispose of any securities of the Company (or any interest therein or in respect thereof) or any other securities exchangeable for, or convertible into, or substantially similar to, Ordinary Shares or enter into any transaction having substantially the same effect or agree to do any of the foregoing other than with the prior written consent of Investec Bank and Liberum (such consent not to be unreasonably withheld or delayed) or in relation to certain permitted staff share scheme grants.

 

Application for admission to trading

Application will be made to the London Stock Exchange for admission of the Placing Shares to trading on AIM.

It is expected that Admission will take place no later than 30 November 2015 and that dealings in the Placing Shares on AIM will commence at the same time.

 

Principal terms of the Placing

1. Investec Bank is acting as nominated adviser and joint broker to the Placing, as agent for and on behalf of the Company. Investec Bank is authorised in the United Kingdom by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, is acting exclusively for the Company and no one else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than the Company for providing the protections afforded to the customers of Investec Bank or for providing advice in relation to the matters described in this Announcement.

2. Liberum is acting as joint broker to the Placing, as agent for and on behalf of the Company. Liberum is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company and no one else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than the Company for providing the protections afforded to the customers of Liberum or for providing advice in relation to the matters described in this Announcement.

3. Participation in the Placing will only be available to persons who may lawfully be, and are, invited by the Banks to participate. Each of the Banks and any of their respective affiliates is entitled to participate in the Placing as principal.

4. The price per Placing Share (the "Placing Price") is fixed at 120 pence and is payable to the relevant Bank by all Placees.

5. Each Placee's allocation is determined by the relevant Bank in its discretion following consultation with the Company and has been or will be confirmed orally by the relevant Bank and a contract note will be dispatched as soon as possible thereafter. That oral confirmation will give rise to an irrevocable, legally binding commitment by that person (who at that point becomes a Placee), in favour of the Banks and the Company, under which it agrees to acquire the number of Placing Shares allocated to the Placee at the Placing Price and otherwise on the terms and subject to the conditions set out in this Appendix and in accordance with the Company's articles of association. Except with the relevant Bank's consent, such commitment will not be capable of variation or revocation at the time at which it is submitted.

6. Each Placee's allocation and commitment will be evidenced by a contract note issued to such Placee by the relevant Bank. The terms of this Appendix will be deemed incorporated in that contract note.

7. Each Placee will have an immediate, separate, irrevocable and binding obligation, owed to the relevant Bank (as agent for the Company), to pay to it (or as it may direct) in cleared funds an amount equal to the product of the Placing Price and the number of Placing Shares such Placee has agreed to acquire and the Company has agreed to allot and issue to that Placee.

8. Irrespective of the time at which a Placee's allocation(s) pursuant to the Placing is/are confirmed, settlement for all Placing Shares to be acquired pursuant to the Placing will be required to be made at the same time, on the basis explained below under "Registration and Settlement".

9. All obligations of the Banks under the Placing will be subject to fulfilment of the conditions referred to below under "Conditions of the Placing" and to the Placing not being terminated on the basis referred to below under "Termination of the Placing".

10. By participating in the Placing, each Placee will agree that its rights and obligations in respect of the Placing will terminate only in the circumstances described below and will not be capable of rescission or termination by the Placee.

11. To the fullest extent permissible by law and applicable FCA rules, none of (a) Investec Bank , (b) any of Investec Bank's affiliates, agents, directors, officers, consultants, (c) to the extent not contained within (a) or (b), any person connected with Investec Bank as defined in the Financial Services and Markets Act 2000 ("FSMA") ((b) and (c) being together "affiliates" and individually an "affiliate" of Investec Bank), (d) any person acting on Investec Bank 's behalf, (e) Liberum, (f) any of Liberum's affiliates, agents, directors, officers, consultants, (g) to the extent not contained within (e) or (f), any person connected with Liberum as defined in FSMA ((f) and (g) being together "affiliates" and individually an "affiliate" of Liberum) or (h) any person acting on Liberum's behalf shall have any liability (including to the extent permissible by law, any fiduciary duties) to Placees or to any other person whether acting on behalf of a Placee or otherwise. In particular, neither of the Banks nor any of their respective affiliates shall have any liability (including, to the extent permissible by law, any fiduciary duties) in respect of their conduct of the Placing or of such alternative method of effecting the Placing as the Banks and the Company may agree.

 

Registration and Settlement

If Placees are allocated any Placing Shares in the Placing they will be sent a contract note or electronic confirmation by the relevant Bank, as soon as it is able which will confirm the number of Placing Shares allocated to them, the Placing Price and the aggregate amount owed by them to the relevant Bank.

Each Placee will be deemed to agree that it will do all things necessary to ensure that delivery and payment is completed as directed by the relevant Bank in accordance with either the standing CREST or certificated settlement instructions which they have in place with the relevant Bank.

Settlement of transactions in the Placing Shares (ISIN: GB00B9F4MT28) following Admission will take place within the CREST system, subject to certain exceptions. Settlement through CREST is expected to take place on 13 November 2015 unless otherwise notified by the Banks and Admission is expected to occur no later than 8.00 a.m. on 13 November 2015 unless otherwise notified by the Banks. Admission and Settlement may occur at an earlier date, which if achievable, will be set out in the Circular. Settlement will be on a delivery versus payment basis. However, in the event of any difficulties or delays in the admission of the Placing Shares to CREST or the use of CREST in relation to the Placing, the Company and each of the Banks may agree that the Placing Shares should be issued in certificated form. Each of the Banks reserves the right to require settlement for the Placing Shares, and to deliver the Placing Shares to Placees, by such other means as they deem necessary if delivery or settlement to Placees is not practicable within the CREST system or would not be consistent with regulatory requirements in a Placee's jurisdiction.

Interest is chargeable daily on payments not received from Placees on the due date in accordance with the arrangements set out above, in respect of either CREST or certificated deliveries, at the rate of 2 percentage points above prevailing LIBOR as determined by the Banks.

Each Placee is deemed to agree that if it does not comply with these obligations, the Banks may sell any or all of their Placing Shares on their behalf and retain from the proceeds, for the Bank's own account and benefit, an amount equal to the aggregate amount owed by the Placee plus any interest due. The relevant Placee will, however, remain liable for any shortfall below the amount owed by it and for any stamp duty or stamp duty reserve tax (together with any interest or penalties) which may arise upon the sale of their Placing Shares on their behalf.

If Placing Shares are to be delivered to a custodian or settlement agent, Placees must ensure that, upon receipt, the conditional contract note is copied and delivered immediately to the relevant person within that organisation. Insofar as Placing Shares are registered in a Placee's name or that of its nominee or in the name of any person for whom a Placee is contracting as agent or that of a nominee for such person, such Placing Shares should, subject as provided below, be so registered free from any liability to United Kingdom stamp duty or stamp duty reserve tax. Placees will not be entitled to receive any fee or commission in connection with the Placing.

 

Conditions of the Placing

The Placing is conditional upon the Placing Agreement becoming unconditional and not having been terminated in accordance with its terms.

The obligations of each of the Banks under the Placing Agreement are, and the Placing is, conditional upon, inter alia:

(a) the passing of the Resolutions (without any amendments not approved by the Banks) at the General Meeting (or at any adjournment thereof);(b) the Takeover Panel providing a Rule 9 Waiver, subject to the Whitewash Resolution being approved by Independent Shareholders;(c) the warranties on the part of the Company contained in the Placing Agreement being true and accurate in all material respects and not misleading on and as of the date of the Placing Agreement and on Admission, as though they had been given and made on such dates by reference to the facts and circumstances then subsisting;(d) the performance by the Company of its obligations under the Placing Agreement to the extent that they fall to be performed prior to Admission;(e) no matter having arisen before Admission which might reasonably be expected to give rise to an indemnity claim under the Placing Agreement;(f) in the opinion of the Banks, acting in good faith, there shall have been no material adverse change since the date of the Placing Agreement (whether or not foreseeable at the date of the Placing Agreement) before Admission; and(g) Admission occurring not later than 8.00 a.m. on 13 November 2015,

(all conditions to the obligations of each of the Banks included in the Placing Agreement being together, the "conditions").

If any of the conditions set out in the Placing Agreement are not fulfilled or, where permitted, waived in accordance with the Placing Agreement within the stated time periods (or such later time and/or date as the Company and the Banks may agree, provided that the time for satisfaction of the condition set out in (g) above shall not be extended beyond 8.00 a.m. on 30 November 2015), or the Placing Agreement is terminated in accordance with its terms, the Placing will lapse and the Placee's rights and obligations shall cease and terminate at such time and each Placee agrees that no claim can be made by or on behalf of the Placee (or any person on whose behalf the Placee is acting) in respect thereof.

By participating in the Placing, each Placee agrees that its rights and obligations cease and terminate only in the circumstances described above and under "Termination of the Placing" below and will not be capable of rescission or termination by it.

Certain conditions may be waived in whole or in part by the Banks, acting jointly, in their absolute discretion by notice in writing to the Company and the Banks may also agree in writing with the Company to extend the time for satisfaction of any condition. Any such extension or waiver will not affect Placees' commitments as set out in this Announcement.

Either of the Banks may terminate the Placing Agreement in certain circumstances, details of which are set out below.

None of the Banks, the Company or any of their respective affiliates, agents, directors, officers, employees shall have any liability to any Placee (or to any other person whether acting on behalf of a Placee or otherwise) in respect of any decision any of them may make as to whether or not to waive or to extend the time and/or date for the satisfaction of any condition to the Placing nor for any decision any of them may make as to the satisfaction of any condition or in respect of the Placing generally and by participating in the Placing each Placee agrees that any such decision is within the absolute discretion of the Banks

 

Termination of the Placing

Either of the Banks may terminate the Placing Agreement, in accordance with its terms, at any time prior to Admission if, inter alia:

1. it comes to the knowledge of either Bank that any of the warranties was untrue, inaccurate or misleading in any material respect; or

2. it comes to the notice of either Bank that any statement contained in this Announcement, or any other document or announcement issued or published by or on behalf of the Company in connection with the Placing, is or has become untrue, incorrect or misleading in any material respect; or

3. the Company shall fail to comply, in any respect which either Bank in its sole opinion believes is material, with any of its obligations under the Placing Agreement; or

4. there has occurred a force majeure event, or any material adverse change has occurred in the financial position or prospects or business of the Company and its subsidiary undertakings (taken as whole) which, in the opinion of either Bank (acting in good faith), would materially prejudice the success of the Placing or the distribution of the Placing Shares.

If the Placing Agreement is terminated in accordance with its terms, the rights and obligations of each Placee in respect of the Placing as described in this Announcement shall cease and terminate at such time and no claim can be made by any Placee in respect thereof.

By participating in the Placing, each Placee agrees with the Company and the Banks that the exercise by the Company or the Banks of any right of termination or any other right or other discretion under the Placing Agreement shall be within the absolute discretion of the Company or the Banks and that neither of the Company nor the Banks need make any reference to such Placee and that none of the Banks, the Company, or any of their respective affiliates, agents, directors, officers or employees shall have any liability to such Placee (or to any other person whether acting on behalf of a Placee or otherwise) whatsoever in connection with any such exercise.

By participating in the Placing, each Placee agrees that its rights and obligations terminate only in the circumstances described above and under the "Conditions of the Placing" section above and will not be capable of rescission or termination by it after the issue by the relevant Bank of a contract note confirming each Placee's allocation and commitment in the Placing.

 

Representations, warranties and further terms

By participating in the Placing, each Placee (and any person acting on such Placee's behalf) represents, warrants, acknowledges and agrees (for itself and for any such prospective Placee) that (save where the Banks expressly agree in writing to the contrary):

1. it has read and understood this Announcement in its entirety and that its acquisition of the Placing Shares is subject to and based upon all the terms, conditions, representations, warranties, indemnities, acknowledgements, agreements and undertakings and other information contained herein and that it has not relied on, and will not rely on, any information given or any representations, warranties or statements made at any time by any person in connection with Admission, the Placing, the Company, the Placing Shares or otherwise, other than the information contained in this Announcement and the Publicly Available Information;

2. it has not received a prospectus or other offering document in connection with the Placing and acknowledges that no prospectus or other offering document: (a) is required under the Prospectus Directive; and (b) has been or will be prepared in connection with the Placing;

3. the Ordinary Shares are admitted to trading on AIM, and that the Company is therefore required to publish certain business and financial information in accordance with the AIM Rules, which includes a description of the nature of the Company's business and the Company's most recent balance sheet and profit and loss account and that it is able to obtain or access such information without undue difficulty, and is able to obtain access to such information or comparable information concerning any other publicly traded company, without undue difficulty;

4. it has made its own assessment of the Placing Shares and has relied on its own investigation of the business, financial or other position of the Company in accepting a participation in the Placing and none of the Banks, the Company or any of their respective affiliates, agents, directors, officers or employees or any person acting on behalf of any of them has provided, and will not provide, it with any material regarding the Placing Shares or the Company or any other person other than the information in this Announcement, or the Publicly Available Information; nor has it requested either of the Banks, the Company, any of their respective affiliates, agents, directors, officers or employees or any person acting on behalf of any of them to provide it with any such information;

5. none of the Banks, any person acting on behalf of them or any of their respective affiliates, agents, directors, officers or employees has or shall have any liability for any Publicly Available Information, or any representation relating to the Company, provided that nothing in this paragraph excludes the liability of any person for fraudulent misrepresentation made by that person;

6. the only information on which it is entitled to rely on and on which it has relied in committing to subscribe for the Placing Shares is contained in the Publicly Available Information, such information being all that it deems necessary to make an investment decision in respect of the Placing Shares and it has made its own assessment of the Company, the Placing Shares and the terms of the Placing based on Publicly Available Information; (b) none of the Banks, the Company or any of their respective affiliates, agents, directors, officers or employees has made any representation or warranty to it, express or implied, with respect to the Company, the Placing or the Placing Shares or the accuracy, completeness or adequacy of the Publicly Available Information; (c) it has conducted its own investigation of the Company, the Placing and the Placing Shares, satisfied itself that the information is still current and relied on that investigation for the purposes of its decision to participate in the Placing; and (d) has not relied on any investigation that the Banks or any person acting on their behalf may have conducted with respect to the Company, the Placing or the Placing Shares;

7. the content of this Announcement and the Publicly Available Information has been prepared by and is exclusively the responsibility of the Company and that neither of the Banks nor any persons acting on behalf of either of them is responsible for or has or shall have any liability for any information, representation, warranty or statement relating to the Company contained in this Announcement or the Publicly Available Information nor will they be liable for any Placee's decision to participate in the Placing based on any information, representation, warranty or statement contained in this Announcement, the Publicly Available Information or otherwise. Nothing in this Appendix shall exclude any liability of any person for fraudulent misrepresentation;

8. the Placing Shares have not been registered or otherwise qualified, and will not be registered or otherwise qualified, for offer and sale nor will a prospectus be cleared or approved in respect of any of the Placing Shares under the securities laws of the United States, or any state or other jurisdiction of the United States, the Republic of Ireland, Australia, Canada, Republic of South Africa or Japan and, subject to certain exceptions, may not be offered, sold, taken up, renounced or delivered or transferred, directly or indirectly, within the United States, the Republic of Ireland, Australia, Canada, South Africa or Japan or in any country or jurisdiction where any such action for that purpose is required;

9. it and/or each person on whose behalf it is participating:

a) is entitled to acquire Placing Shares pursuant to the Placing under the laws and regulations of all relevant jurisdictions;b) has fully observed such laws and regulations;c) has capacity and authority and is entitled to enter into and perform its obligations as an acquirer of Placing Shares and will honour such obligations; andd) has obtained all necessary consents and authorities (including, without limitation, in the case of a person acting on behalf of a Placee, all necessary consents and authorities to agree to the terms set out or referred to in this Appendix) under those laws or otherwise and complied with all necessary formalities to enable it to enter into the transactions contemplated hereby and to perform its obligations in relation thereto and, in particular, if it is a pension fund or investment company it is aware of and acknowledges it is required to comply with all applicable laws and regulations with respect to its subscription for Placing Shares;

10. it is not, and any person who it is acting on behalf of is not, and at the time the Placing Shares are subscribed will not be, a resident of, or with an address in, or subject to the laws of, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, and it acknowledges and agrees that the Placing Shares have not been and will not be registered or otherwise qualified under the securities legislation of Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa and may not be offered, sold, or acquired, directly or indirectly, within those jurisdictions;

11. the Placing Shares have not been, and will not be, registered under the Securities Act and may not be offered, sold or resold in or into or from the United States except pursuant to an effective registration under the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with applicable state securities laws; and no representation is being made as to the availability of any exemption under the Securities Act for the reoffer, resale, pledge or transfer of the Placing Shares;

12. it and the beneficial owner of the Placing Shares is, and at the time the Placing Shares are acquired will be, outside the United States and acquiring the Placing Shares in an "offshore transaction" as defined in, and in accordance with, Regulation S under the Securities Act;

13. it (and any account for which it is purchasing) is not acquiring the Placing Shares with a view to any offer, sale or distribution thereof within the meaning of the Securities Act;

14. it will not distribute, forward, transfer or otherwise transmit this Announcement or any part of it, or any other presentational or other materials concerning the Placing in or into or from the United States (including electronic copies thereof) to any person, and it has not distributed, forwarded, transferred or otherwise transmitted any such materials to any person;

15. none of the Banks, their respective affiliates, agents, directors, officers or employees and any person acting on behalf of any of them is making any recommendations to it, advising it regarding the suitability of any transactions it may enter into in connection with the Placing and that participation in the Placing is on the basis that it is not and will not be a client of either of the Banks and neither of the Banks has any duties or responsibilities to it for providing the protections afforded to its clients or for providing advice in relation to the Placing nor in respect of any representations, warranties, undertakings or indemnities contained in the Placing Agreement nor for the exercise or performance of any of its rights and obligations thereunder including any rights to waive or vary any conditions or exercise any termination right;

16. it has the funds available to pay for the Placing Shares for which it has agreed to subscribe and acknowledges and agrees that it will make payment to the relevant Bank for the Placing Shares allocated to it in accordance with the terms and conditions of this Announcement on the due times and dates set out in this Announcement, failing which the relevant Placing Shares may be placed with others on such terms as the Banks may, in their absolute discretion determine without liability to the Placee and it will remain liable for any shortfall below the net proceeds of such sale and the placing proceeds of such Placing Shares and may be required to bear any stamp duty or stamp duty reserve tax (together with any interest or penalties due pursuant to the terms set out or referred to in this Announcement) which may arise upon the sale of such Placee's Placing Shares on its behalf;

17. no action has been or will be taken by any of the Company, the Banks or any person acting on their behalf that would, or is intended to, permit a public offer of the Placing Shares in the United States or in any country or jurisdiction where any such action for that purpose is required;

18. the person who it specifies for registration as holder of the Placing Shares will be: (a) the Placee; or (b) a nominee of the Placee, as the case may be. Neither the Banks nor the Company will be responsible for any liability to stamp duty or stamp duty reserve tax resulting from a failure to observe this requirement. Each Placee and any person acting on behalf of such Placee agrees to acquire Placing Shares pursuant to the Placing and agrees to pay the Company and the Banks in respect of the same (including any interest or penalties) on the basis that the Placing Shares will be allotted to a CREST stock account of either of the Banks or transferred to a CREST stock account of either of the Banks who will hold them as nominee on behalf of the Placee until settlement in accordance with its standing settlement instructions with it;

19. it is acting as principal only in respect of the Placing or, if it is acting for any other person, (a) it is duly authorised to do so and has full power to make the acknowledgments, representations and agreements herein on behalf of each such person and (b) it is and will remain liable to the Company and the Banks for the performance of all its obligations as a Placee in respect of the Placing (regardless of the fact that it is acting for another person);

20. the allocation, allotment, issue and delivery to it, or the person specified by it for registration as holder, of Placing Shares will not give rise to a stamp duty or stamp duty reserve tax liability under (or at a rate determined under) any of sections 67, 70, 93 or 96 of the Finance Act 1986 (depository receipts and clearance services) and that it is not participating in the Placing as nominee or agent for any person or persons to whom the allocation, allotment, issue or delivery of Placing Shares would give rise to such a liability;

21. it and any person acting on its behalf (if within the United Kingdom) falls within Article 19(5) and/or 49(2) of the Order and undertakes that it will acquire, hold, manage and (if applicable) dispose of any Placing Shares that are allocated to it for the purposes of its business only;

22. it will not make an offer to the public of the Placing Shares and it has not offered or sold and will not offer or sell any Placing Shares to persons in the United Kingdom or elsewhere in the EEA prior to the expiry of a period of six months from Admission except to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of their business or otherwise in circumstances which have not resulted and which will not result in an offer to the public in the United Kingdom within the meaning of section 85(1) of the FSMA or an offer to the public in any other member state of the EEA within the meaning of the Prospectus Directive;

23. it is a person of a kind described in: (a) Article 19(5) (Investment Professionals) and/or 49(2) (High net worth companies etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, and/or an authorised person as defined in section 31 of FSMA; and (b) section 86(7) of FSMA ("Qualified Investor"), being a person falling within Article 2.1(e) the Prospectus Directive. For such purposes, it undertakes that it will acquire, hold, manage and (if applicable) dispose of any Placing Shares that are allocated to it for the purposes of its business only;

24. it has only communicated or caused to be communicated and it will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) relating to Placing Shares in circumstances in which section 21(1) of the FSMA does not require approval of the communication by an authorised person and it acknowledges and agrees that neither of the Banks has approved this Announcement in their capacity as authorised persons under section 21 of FSMA and it may not therefore be subject to the controls which would apply if it was made or approved as financial promotion by an authorised person;

25. it has complied and it will comply with all applicable laws with respect to anything done by it or on its behalf in relation to the Placing Shares (including all relevant provisions of the FSMA in respect of anything done in, from or otherwise involving the United Kingdom);

26. represents and warrants that, if it is a financial intermediary, as that term is used in Article 3(2) of the Prospectus Directive (including any relevant implementing measure in any member state), the Placing Shares acquired by it in the Placing will not be acquired on a non-discretionary basis on behalf of, nor will they be acquired with a view to their offer or resale to, persons in a member state of the EEA which has implemented the Prospectus Directive other than Qualified Investors, or in circumstances in which the express prior written consent of the Banks has been given to the offer or resale;

27. it has neither received nor relied on any confidential price sensitive information about the Company in accepting this invitation to participate in the Placing;

28. none of the Banks, any of their respective affiliates, agents, directors, officers or employees or any person acting on behalf of any of them has or shall have any liability for any information, representation or statement contained in this Announcement or for any information previously published by or on behalf of the Company or any other written or oral information made available to or publicly available or filed information or any representation, warranty or undertaking relating to the Company, and will not be liable for its decision to participate in the Placing based on any information, representation, warranty or statement contained in this Announcement or elsewhere, provided that nothing in this paragraph shall exclude any liability of any person for fraud;

29. none of the Banks, the Company, any of their respective affiliates, agents, directors, officers or employees or any person acting on behalf of the Banks, the Company or their respective affiliates, agents, directors, officers or employees is making any recommendations to it, advising it regarding the suitability of any transactions it may enter into in connection with the Placing nor providing advice in relation to the Placing nor in respect of any representations, warranties, acknowledgements, agreements, undertakings, or indemnities contained in the Placing Agreement nor the exercise or performance of each of the Banks' rights and obligations thereunder including any rights to waive or vary any conditions or exercise any termination right;

30. acknowledges and accepts that the Banks may, in accordance with applicable legal and regulatory provisions, engage in transactions in relation to the Placing Shares and/or related instruments for their own account for the purpose of hedging their underwriting exposure or otherwise and, except as required by applicable law or regulation, neither of the Banks will make any public disclosure in relation to such transactions;

31. the Banks and each of their respective affiliates, each acting as an investor for its or their own account(s), may bid or subscribe for and/or purchase Placing Shares and, in that capacity, may retain, purchase, offer to sell or otherwise deal for its or their own account(s) in the Placing Shares, any other securities of the Company or other related investments in connection with the Placing or otherwise. Accordingly, references in this Announcement to the Placing Shares being offered, subscribed, acquired or otherwise dealt with should be read as including any offer to, or subscription, acquisition or dealing by the Banks and/or any of their respective affiliates, acting as an investor for its or their own account(s). Neither the Banks nor the Company intend to disclose the extent of any such investment or transaction otherwise than in accordance with any legal or regulatory obligation to do so;

32. it has not offered or sold and will not offer or sell any Placing Shares to persons in the EEA prior to the expiry of a period of six months from Admission except to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or agent) for the purpose of their business or otherwise in circumstances which have not resulted and which will not result in an offer to the public in any member state of the EEA within the meaning of the Prospectus Directive;

33. it has complied with its obligations in connection with money laundering and terrorist financing under the Proceeds of Crime Act 2002, the Terrorism Act 2000, the Terrorism Act 2006 and the Money Laundering Regulations 2007 (together, the "Regulations") and, if making payment on behalf of a third party, that satisfactory evidence has been obtained and recorded by it to verify the identity of the third party as required by the Regulations;

34. it is aware of the obligations regarding insider dealing in the Criminal Justice Act 1993, section 118 of FSMA and the Proceeds of Crime Act 2002 and confirms that it has and will continue to comply with those obligations;

35. in order to ensure compliance with the Money Laundering Regulations 2007, the Banks (each for itself and as agent on behalf of the Company) or the Company's registrars may, in their absolute discretion, require verification of its identity. Pending the provision to the Banks or the Company's registrars, as applicable, of evidence of identity, definitive certificates in respect of the Placing Shares may be retained at the relevant Bank's absolute discretion or, where appropriate, delivery of the Placing Shares to it in uncertificated form may be delayed at the Banks or the Company's registrars', as the case may be, absolute discretion. If within a reasonable time after a request for verification of identity the Banks (each for itself and as agent on behalf of the Company) or the Company's registrars have not received evidence satisfactory to them, the Banks and/or the Company may, at its absolute discretion, terminate its commitment in respect of the Placing, in which event the monies payable on acceptance of allotment will, if already paid, be returned without interest to the account of the drawee's bank from which they were originally debited;

36. acknowledges that its commitment to acquire Placing Shares on the terms set out in this Announcement and in the contract note will continue notwithstanding any amendment that may in future be made to the terms and conditions of the Placing and that Placees will have no right to be consulted or require that their consent be obtained with respect to the Company's or the Banks conduct of the Placing;

37. it has knowledge and experience in financial, business and international investment matters as is required to evaluate the merits and risks of subscribing for the Placing Shares. It further acknowledges that it is experienced in investing in securities of this nature and is aware that it may be required to bear, and is able to bear, the economic risk of, and is able to sustain, a complete loss in connection with the Placing. It has relied upon its own examination and due diligence of the Company and its affiliates taken as a whole, and the terms of the Placing, including the merits and risks involved;

38. it irrevocably appoints any duly authorised officer of the Banks as its agent for the purpose of executing and delivering to the Company and/or its registrars any documents on its behalf necessary to enable it to be registered as the holder of any of the Placing Shares for which it agrees to subscribe or purchase upon the terms of this Announcement;

39. the Company, the Banks and others (including each of their respective affiliates, agents, directors, officers or employees) will rely upon the truth and accuracy of the foregoing representations, warranties, acknowledgements and agreements, which are given to the Banks, each on their own behalf and on behalf of the Company and are irrevocable;

40. if it is acquiring the Placing Shares as a fiduciary or agent for one or more investor accounts, it has full power and authority to make, and does make, the foregoing representations, warranties, acknowledgements, agreements and undertakings on behalf of each such accounts;

41. time is of the essence as regards its obligations under this Appendix;

42. any document that is to be sent to it in connection with the Placing will be sent at its risk and may be sent to it at any address provided by it to the Banks;

43. the Placing Shares will be issued subject to the terms and conditions of this Appendix; and

44. these terms and conditions in this Appendix and all documents into which this Appendix is incorporated by reference or otherwise validly forms a part and/or any agreements entered into pursuant to these terms and conditions and all agreements to acquire shares pursuant to the Placing will be governed by and construed in accordance with English law and it submits to the exclusive jurisdiction of the English courts in relation to any claim, dispute or matter arising out of any such contract, except that enforcement proceedings in respect of the obligation to make payment for the Placing Shares (together with any interest chargeable thereon) may be taken by the Company or the Banks in any jurisdiction in which the relevant Placee is incorporated or in which any of its securities have a quotation on a recognised stock exchange.

 

By participating in the Placing, each Placee (and any person acting on such Placee's behalf) agrees to indemnify and hold the Company, the Banks and each of their respective affiliates, agents, directors, officers and employees harmless from any and all costs, claims, liabilities and expenses (including legal fees and expenses) arising out of or in connection with any breach of the representations, warranties, acknowledgements, agreements and undertakings given by the Placee (and any person acting on such Placee's behalf) in this Appendix or incurred by the Banks, the Company or each of their respective affiliates, agents, directors, officers or employees arising from the performance of the Placee's obligations as set out in this Announcement, and further agrees that the provisions of this Appendix shall survive after the completion of the Placing.

The agreement to allot and issue Placing Shares to Placees (or the persons for whom Placees are contracting as agent) free of stamp duty and stamp duty reserve tax in the United Kingdom relates only to their allotment and issue to Placees, or such persons as they nominate as their agents, direct by the Company. Such agreement assumes that the Placing Shares are not being acquired in connection with arrangements to issue depositary receipts or to transfer the Placing Shares into a clearance service. If there are any such arrangements, or the settlement related to any other dealings in the Placing Shares, stamp duty or stamp duty reserve tax may be payable. In that event, the Placee agrees that it shall be responsible for such stamp duty or stamp duty reserve tax and neither the Company nor the Banks shall be responsible for such stamp duty or stamp duty reserve tax. If this is the case, each Placee should seek its own advice and they should notify the Banks accordingly. In addition, Placees should note that they will be liable for any capital duty, stamp duty and all other stamp, issue, securities, transfer, registration, documentary or other duties or taxes (including any interest, fines or penalties relating thereto) payable outside the United Kingdom by them or any other person on the acquisition by them of any Placing Shares or the agreement by them to acquire any Placing Shares and each Placee, or the Placee's nominee, in respect of whom (or in respect of the person for whom it is participating in the Placing as an agent or nominee) the allocation, allotment, issue or delivery of Placing Shares has given rise to such non-United Kingdom stamp, registration, documentary, transfer or similar taxes or duties undertakes to pay such taxes and duties, including any interest and penalties (if applicable), forthwith and to indemnify on an after-tax basis and to hold harmless the Company and the Banks in the event that either the Company and/or the Banks have incurred any such liability to such taxes or duties.

The representations, warranties, acknowledgements and undertakings contained in this Appendix are given to each of the Banks for itself and on behalf of the Company and are irrevocable.

Each Placee and any person acting on behalf of the Placee acknowledges that the Banks do not owe any fiduciary or other duties to any Placee in respect of any representations, warranties, undertakings, acknowledgements, agreements or indemnities in the Placing Agreement.

Each Placee and any person acting on behalf of the Placee acknowledges and agrees that the Banks may (at their absolute discretion) satisfy their obligations to procure Placees by itself agreeing to become a Placee in respect of some or all of the Placing Shares or by nominating any connected or associated person to do so.

When a Placee or any person acting on behalf of the Placee is dealing with the relevant Bank, any money held in an account with the relevant Bank on behalf of the Placee and/or any person acting on behalf of the Placee will not be treated as client money within the meaning of the relevant rules and regulations of the FCA made under FSMA. Each Placee acknowledges that the money will not be subject to the protections conferred by the client money rules: as a consequence this money will not be segregated from the relevant Bank's money (as applicable) in accordance with the client money rules and will be held by it under a banking relationship and not as trustee.

References to time in this Announcement are to London time, unless otherwise stated.

All times and dates in this Announcement may be subject to amendment.

No statement in this Announcement is intended to be a profit forecast, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.

The Placing Shares to be issued or sold pursuant to the Placing will not be admitted to trading on any stock exchange other than the London Stock Exchange.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEDGGDCSUXBGUG
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.